BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 23, 2006
View Archived Issues
Adventrx Moves Into Phase III With CoFactor, Pulls Offering
Adventrx Pharmaceuticals Inc. and the FDA have agreed on a special protocol assessment for a Phase III trial of its chemotherapy enhancing drug, CoFactor, expected to start this quarter. (BioWorld Today)
Read More
U3 Pharma Raises €27M For Preclinical Cancer Products
No Abstract
Read More
ImaRx Seeking $75M IPO For Anti-Clotting Products
Read More
SEC Signaling Interest In Scaling Back SOX Rules
Read More
Naryx Series B2 Financing Gets $8M For Chronic Sinusitis Drug
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Appointments And Advancements
Read More